Company intelligence / Profile preview
Vcanbio Cell & Gene Engineering Corp., Ltd.
Tianjin, Tianjin, Chinavcanbio.com ↗
- Ownership
- Private
- Employees
- ~2014
- Development stage
- Commercial
01
Overview
The company has multiple programs in clinical development, with VUM-02 in Phase 2 for Steroid Refractory Graft Versus Host Disease, YW-CARCD19-T in Phase 1 for B-Cell Leukemia, and VUM-03 with IND Approval for Perianal fistula due to Crohn's disease.
- Therapeutic areas
- OncologyImmunologyGastroenterology
- Modalities
- Stem cell therapyCAR-TMonoclonal antibodyMesenchymal stem cell therapyCytokine-induced Killer Cell (CIK)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Lanzhou University
Beyond the preview
Go deeper on Vcanbio Cell & Gene Engineering Corp., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vcanbio Cell & Gene Engineering Corp., Ltd..